BIOCORNEUM, the brand behind what it declares the top scar treatment recommended by U.S. plastic surgeons, is broadening its scar recovery offering with the launch of SiliSilk, a non-SPF professional-grade silicone formula in a lightweight, non-greasy gel format. The non-SPF positioning makes it particularly suited for indoor use or areas covered by clothing, where sun protection is not required.
Silicone remains the most widely recommended non-invasive topical treatment for scar management across international clinical guidelines, and BIOCORNEUM is leaning into that consensus with a format aimed at everyday recovery and long-term compliance.
The launch comes as the global scar treatment market accelerates. The category was estimated to reach $19.1 billion in 2025, per Future Market Insights, and is projected to more than double to $43.5 billion by 2035, growing at a CAGR of 8.7%. Demand is being driven by rising aesthetic awareness, increased surgical and cosmetic procedures, and a shift toward clinically validated, patient-centric therapies.
Within that landscape, topical treatments—particularly silicone-based formulations—remain a preferred first-line option, thanks to their accessibility and ease of use, even as advanced modalities like lasers, microneedling and minimally invasive procedures gain traction.
SiliSilk at a glance
- Creates an optimal healing environment: Forms an oxygen- and moisture-rich barrier to support natural repair and help reduce hypertrophic and keloid scarring, per the brand.
- Cosmetically elegant: Fast-drying, non-greasy texture suitable for face, neck, joints and high-movement areas; makeup or clothing can be applied once dry.
- Versatile indications: Effective on new and existing scars from surgery, cosmetic procedures, trauma, wounds and burns; also appropriate for stretch marks, fine lines and wrinkles.
- Patient-friendly format: A self-adhering, breathable “second skin” that eliminates the need for tape or silicone sheets.
“Our focus has always been delivering silicone scar therapy clinicians can trust,” said Kristy Matus, vice president of product management. “SiliSilk extends that clinically proven technology into a non-SPF format designed for everyday recovery—giving patients more choice without compromising clinical rigor.”
